Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.
作者信息
Hughes Jing, Vudattu Nalini, Sznol Mario, Gettinger Scott, Kluger Harriet, Lupsa Beatrice, Herold Kevan C
机构信息
Department of Immunobiology, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT Section of Endocrinology and Metabolism, Yale University School of Medicine, New Haven, CT.
Department of Immunobiology, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT.
出版信息
Diabetes Care. 2015 Apr;38(4):e55-7. doi: 10.2337/dc14-2349.
Abstract
摘要
相似文献
1
Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.
Diabetes Care. 2015 Apr;38(4):e55-7. doi: 10.2337/dc14-2349.
2
Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.
J Diabetes Investig. 2018 Mar;9(2):448-449. doi: 10.1111/jdi.12662.
3
PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
J Clin Endocrinol Metab. 2018 Oct 1;103(10):3589-3592. doi: 10.1210/jc.2018-01430.
4
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
Cancer Immunol Immunother. 2018 Aug;67(8):1197-1208. doi: 10.1007/s00262-018-2178-0. Epub 2018 May 28.
5
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.
N Engl J Med. 2015 Jul 16;373(3):288-90. doi: 10.1056/NEJMc1505197.
6
Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes.
Diabetes Care. 2015 Sep;38(9):e137-8. doi: 10.2337/dc15-0889. Epub 2015 Jun 26.
7
Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
J Diabetes Investig. 2016 Nov;7(6):915-918. doi: 10.1111/jdi.12531. Epub 2016 May 31.
8
A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.
Immunotherapy. 2017 Jun;9(7):531-535. doi: 10.2217/imt-2017-0020.
9
Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
J Clin Endocrinol Metab. 2015 May;100(5):1738-41. doi: 10.1210/jc.2014-4560. Epub 2015 Mar 9.
10
Efficacy of PD-1 blockade in tumors with MMR deficiency.
Immunotherapy. 2016;8(1):1-3. doi: 10.2217/imt.15.97. Epub 2015 Dec 8.
引用本文的文献
1
PD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis.
Front Immunol. 2025 Aug 13;16:1644903. doi: 10.3389/fimmu.2025.1644903. eCollection 2025.
2
Rapid Onset of Fulminant Type 1 Diabetes 10 Days After the First Dose of Nivolumab: A Case Report.
Cureus. 2025 Jun 13;17(6):e85957. doi: 10.7759/cureus.85957. eCollection 2025 Jun.
3
Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment.
Acta Pharm Sin B. 2025 Mar;15(3):1230-1241. doi: 10.1016/j.apsb.2024.10.014. Epub 2024 Nov 4.
4
Utility of Estimating Glycated Hemoglobin in Sodium Fluoride Tube and by Turbidimetric Immunoinhibition Method: Our Experience in a Tertiary Care Cancer Centre.
Cureus. 2025 Mar 25;17(3):e81164. doi: 10.7759/cureus.81164. eCollection 2025 Mar.
5
Onset of Type 1 Diabetes Mellitus Five Months After Pembrolizumab Therapy for Nodular Melanoma: A Case Report.
Cureus. 2025 Mar 5;17(3):e80083. doi: 10.7759/cureus.80083. eCollection 2025 Mar.
6
Enhancing anti-CD3 mAb-mediated diabetes remission in autoimmune diabetes through regulation of dynamin-related protein 1(Drp1)-mediated mitochondrial dynamics in exhausted CD8T-cell subpopulations.
BMC Med. 2025 Mar 31;23(1):189. doi: 10.1186/s12916-025-04001-5.
7
Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments.
Pharmacol Rev. 2025 Mar;77(2):100044. doi: 10.1016/j.pharmr.2025.100044. Epub 2025 Jan 23.
8
A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis.
Front Immunol. 2024 Nov 4;15:1448728. doi: 10.3389/fimmu.2024.1448728. eCollection 2024.
9
Usefulness of urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors.
Support Care Cancer. 2024 Oct 18;32(11):735. doi: 10.1007/s00520-024-08928-y.
10
Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment.
Biomedicines. 2024 Aug 19;12(8):1886. doi: 10.3390/biomedicines12081886.
本文引用的文献
1
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
2
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
3
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
4
Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers.
Diabetes. 2010 Jul;59(7):1721-30. doi: 10.2337/db09-1486. Epub 2010 Mar 31.
5
Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.
Clin Immunol. 2010 Feb;134(2):121-9. doi: 10.1016/j.clim.2009.09.005.
Zotero 插件